Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird
Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on ...
HC Wainwright Has Bullish Forecast for DNLI FY2028 Earnings
HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...
Denali Therapeutics (NASDAQ:DNLI) Given New $87.00 Price Target at HC Wainwright
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...
Biggest stock movers Tuesday: NARI, DNLI, and more
Stock futures were mixed in Tuesday’s premarket session as investors looked ahead to the release of the Job Openings and ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
ETF Daily News3d
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.1% on Insider Selling
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) shares traded down 4.1% on Monday following insider selling activity. The stock traded as low as $20.25 and last traded at $20.39.
Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato Sells 3,080 Shares of Stock
Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The ...
ETF Daily News5d
William Blair Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)
Shares of DNLI stock opened at $21.26 on Friday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a fifty day moving average of $24.62 and a 200-day ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathwaySOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 ...